UK markets close in 1 hour 50 minutes

Basilea Pharmaceutica AG (BPMUF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
40.750.00 (0.00%)
As of 02:09PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close40.75
Open40.75
Bid0.00 x 0
Ask0.00 x 0
Day's range40.75 - 40.75
52-week range38.60 - 52.00
Volume5
Avg. volume3
Market cap501.302M
Beta (5Y monthly)0.56
PE ratio (TTM)42.45
EPS (TTM)0.96
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

    Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

  • Globe Newswire

    Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

    Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024 guidance:

  • Globe Newswire

    Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

    Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region. David Veitch, Chief Executive